Cross-reactive antibodies enhance live attenuated virus infection for increased immunogenicity

Nature Microbiology

Volumn 1, Issue , 2016, Pages

  Chan, Kuan Rong ^a   Wang, Xiaohui ^a   Saron, Wilfried A A ^a   Gan, Esther Shuyi ^a   Tan, Hwee Cheng ^a   Mok, Darren Z L ^b   Zhang, Summer Li Xin ^a   Lee, Yie Hou ^c,d   Liang, Cui ^c   Wijaya, Limin ^e   Ghosh, Sujoy ^a   Cheung, Yin Bun ^a   Tannenbaum, Steven R ^a,f,g   Abraham, Soman N ^a,h   St John, Ashley L ^e   Low, Jenny G H ^a,b,c   Ooi, Eng Eong ^b  

^a DUKE NUS MEDICAL SCHOOL   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c SINGAPORE MIT ALLIANCE FOR RESEARCH AND TECHNOLOGY   (Singapore)

^d K K Women's and Children's Hospital   (Singapore)

^e SINGAPORE GENERAL HOSPITAL   (Singapore)

^f TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^g MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^h DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84988410065     PISSN: None     EISSN: 20585276     Source Type: Journal    
DOI: 10.1038/nmicrobiol.2016.164     Document Type: Article

References (53)

1. Pike, B. L. et al. The origin and prevention of pandemics. Clin. Infect. Dis. 50, 1636-1640 (2010).
2. Fauci, A. S. & Morens, D. M. Zika virus in the Americas-yet another arbovirus threat. N. Engl. J. Med. 374, 601-604 (2016).
3. WHO Ebola Response Team. Ebola virus disease in West Africa-The first 9 months of the epidemic and forward projections. N. Engl. J. Med. 371, 1481-1495 (2014).
4. DArgenio, D. A. &Wilson, C. B. A decade of vaccines: integrating immunology and vaccinology for rational vaccine design. Immunity 33, 437-440 (2010).
5. Rappuoli, R., Mandl, C. W., Black, S. & De Gregorio, E. Vaccines for the twenty-first century society. Nat. Rev. Immunol. 11, 865-872 (2011).
6. Henao-Restrepo, A. M. et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet 386, 857-866 (2015).
7. Buchbinder, S. P. et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): A double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372, 1881-1893 (2008).
8. Davenport, F. M., Hennessy, A. V. & Francis, T. Jr Epidemiologic and immunologic significance of age distribution of antibody to antigenic variants of influenza virus. J. Exp. Med. 98, 641-656 (1953).
9. Hadinegoro, S. R. et al. Efficacy and long-Term safety of a dengue vaccine in regions of endemic disease. N. Engl. J. Med. 373, 1195-1206 (2015).
10. Villar, L. et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N. Engl. J. Med. 372, 113-123 (2015).
11. Capeding, M. R. et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: A phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 384, 1358-1365 (2014).
12. Halstead, S. B., Mahalingam, S., Marovich, M. A., Ubol, S. & Mosser, D. M. Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes. Lancet Infect. Dis. 10, 712-722 (2010).
13. Chan, K. R. et al. Leukocyte immunoglobulin-like receptor B1 is critical for antibody-dependent dengue. Proc. Natl Acad. Sci. USA 111, 2722-2727 (2014).
14. Boonnak, K., Dambach, K. M., Donofrio, G. C., Tassaneetrithep, B. & Marovich, M. A. Cell type specificity and host genetic polymorphisms influence antibody-dependent enhancement of dengue virus infection. J. Virol. 85, 1671-1683 (2011).
15. Campi-Azevedo, A. C. et al. Subdoses of 17DD yellow fever vaccine elicit equivalent virological/immunological kinetics timeline. BMC Infect. Dis. 14, 391 (2014).
16. Subramanian, A. et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545-15550 (2005).
17. Gaucher, D. et al. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J. Exp. Med. 205, 3119-3131 (2008).
18. Querec, T. D. et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat. Immunol. 10, 116-125 (2009).
19. McKinney, E. F., Lee, J. C., Jayne, D. R., Lyons, P. A. & Smith, K. G. T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection. Nature 523, 612-616 (2015).
20. Acuto, O. & Michel, F. CD28-mediated co-stimulation: A quantitative support for TCR signalling. Nat. Rev. Immunol. 3, 939-951 (2003).
21. Boyman, O. & Sprent, J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat. Rev. Immunol. 12, 180-190 (2012).
22. Suzuki, K., Kumanogoh, A. & Kikutani, H. Semaphorins and their receptors in immune cell interactions. Nat. Immunol. 9, 17-23 (2008).
23. Takamatsu, H. & Kumanogoh, A. Diverse roles for semaphorin-plexin signaling in the immune system. Trends Immunol. 33, 127-135 (2012).
24. Kolodkin, A. L., Matthes, D. J. & Goodman, C. S. The semaphorin genes encode a family of transmembrane and secreted growth cone guidance molecules. Cell 75, 1389-1399 (1993).
25. Kumanogoh, A. et al. Class IV semaphorin Sema4A enhances T-cell activation and interacts with Tim-2. Nature 419, 629-633 (2002).
26. Suzuki, K. et al. Semaphorin 7A initiates T-cell-mediated inflammatory responses through α1β1 integrin. Nature 446, 680-684 (2007).
27. van Rijn, A. et al. Semaphorin 7A promotes chemokine-driven dendritic cell migration. J. Immunol. 196, 459-468 (2016).
28. Daynes, R. A., Dowell, T. & Araneo, B. A. Platelet-derived growth factor is a potent biologic response modifier of T cells. J. Exp. Med. 174, 1323-1333 (1991).
29. Gavalas, N. G. et al. VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2. Br. J. Cancer 107, 1869-1875 (2012).
30. Ziogas, A. C. et al. VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor Type 2. Int. J. Cancer 130, 857-864 (2012).
31. Liu, Y. et al. Regulated expression of FcgammaR in human dendritic cells controls cross-presentation of antigen-Antibody complexes. J. Immunol. 177, 8440-8447 (2006).
32. Guzman, M. G. et al. Dengue hemorrhagic fever in Cuba, 1981: A retrospective seroepidemiologic study. Am. J. Trop. Med. Hyg. 42, 179-184 (1990).
33. de Alwis, R. et al. Dengue viruses are enhanced by distinct populations of serotype cross-reactive antibodies in human immune sera. PLoS Pathogens 10, e1004386 (2014).
34. Halstead, S. B. & ORourke, E. J. Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody. J. Exp. Med. 146, 201-217 (1977).
35. Olkowski, S. et al. Reduced risk of disease during postsecondary dengue virus infections. J. Infect. Dis. 208, 1026-1033 (2013).
36. Thanachartwet, V. et al. Identification of clinical factors associated with severe dengue among Thai adults: A prospective study. BMC Infect. Dis. 15, 420 (2015).
37. Ben Mkaddem, S. et al. Shifting FcyRIIA-ITAM from activation to inhibitory conFig.uration ameliorates arthritis. J. Clin. Invest. 124, 3945-3959 (2014).
38. Aloulou, M. et al. IgG1 and IVIg induce inhibitory ITAM signaling through FcyRIII controlling inflammatory responses. Blood 119, 3084-3096 (2012).
39. Chan, K. R. et al. Ligation of Fc y receptor IIB inhibits antibody-dependent enhancement of dengue virus infection. Proc. Natl Acad. Sci. USA 108, 12479-12484 (2011).
40. Lennartz, M. R. & Brown, E. J. Arachidonic acid is essential for IgG Fc receptormediated phagocytosis by human monocytes. J. Immunol. 147, 621-626 (1991).
41. Stachowska, E. et al. Conjugated linoleic acids can change phagocytosis of human monocytes/macrophages by reduction in Cox-2 expression. Lipids 42, 707-716 (2007).
42. Middleton, M. K., Rubinstein, T. & Pure, E. Cellular and molecular mechanisms of the selective regulation of IL-12 production by 12/15-lipoxygenase. J. Immunol. 176, 265-274 (2006).
43. Calder, P. C. & Grimble, R. F. Polyunsaturated fatty acids, inflammation and immunity. Eur. J. Clin. Nutr. 56(Suppl. 3), S14-S19 (2002).
44. Pulendran, B. Systems vaccinology: probing humanitys diverse immune systems with vaccines. Proc. Natl Acad. Sci. USA 111, 12300-12306 (2014).
45. Casanova, J. L. & Abel, L. The genetic theory of infectious diseases: A brief history and selected illustrations. Annu. Rev. Genom. Hum. Genet. 14, 215-243 (2013).
46. Kau, A. L., Ahern, P. P., Griffin, N. W., Goodman, A. L. & Gordon, J. I. Human nutrition, the gut microbiome and the immune system. Nature 474, 327-336 (2011).
47. Goh, K. C. et al. Molecular determinants of plaque size as an indicator of dengue virus attenuation. Sci. Rep. 6, 26100 (2016).
48. Jafari, H. et al. Polio eradication. Efficacy of inactivated poliovirus vaccine in India. Science 345, 922-925 (2014).
49. Bass, J.W. et al. Booster vaccination with further live attenuated measles vaccine. JAMA 235, 31-34 (1976).
50. Low, J. G. et al. The role of pre-existing cross-reactive antibodies in determining the efficacy of vaccination in humans: study protocol for a randomized controlled trial. Trials 16, 147 (2015).
51. Domingo, C. et al. Advanced yellow fever virus genome detection in point-of-care facilities and reference laboratories. J. Clin. Microbiol. 50, 4054-4060 (2012).
52. Cui, L. et al. Serum metabolome and lipidome changes in adult patients with primary dengue infection. PLoS Negl. Trop. Dis. 7, e2373 (2013).
53. Hanson, B. J. et al. Passive immunoprophylaxis and therapy with humanized monoclonal antibody specific for influenza A H5 hemagglutinin in mice. Respir. Res. 7, 126 (2006).